Burn News and Research

RSS

Small gifts to boost the spirits of cancer patients

"When a person receives a cancer diagnosis his or her life is completely transformed and all of the sudden they have so few choices," said Laura Morrell, social worker at Loyola University Health System's Cardinal Bernardin Cancer Center. Thirty-five women and one man who attend the Divine Savior Parish in Downers Grove, Ill., are helping to bring choice back into cancer patients' lives.

27 Mar 2010

One-stop resource for advanced wound care medical reimbursement on Smith & Nephew website

The Advanced Wound Management Division of Smith & Nephew, Inc., a subsidiary of Smith & Nephew plc, is providing a web-based resource guide to medical reimbursement for its comprehensive line of advanced wound care products.

27 Mar 2010

JCOM receives approval from KFDA to commercialize MuGard in Korea

ACCESS PHARMACEUTICALS, INC. announced that JCOM Co., Ltd., its Korean licensee for both MuGard™ and ProLindac™, has received approval from the Korean Food and Drug Administration of its Registration Dossier for MuGard, an oncology supportive-care treatment for the management of oral mucositis.

26 Mar 2010

MediciNova reports net loss of $5.9 million for 2009 fourth quarter

MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced financial results for the fourth quarter and full year ended December 31, 2009.

25 Mar 2010

Garnet BioTherapeutics commences treatment in GBT009 trial for incisional wounds following breast reconstruction surgery

Garnet BioTherapeutics, Inc., a regenerative medicine company focused on developing cell based therapies, today announced that the first patient has been treated in a Phase 2 multicenter, double-blind, placebo-controlled study of its lead product candidate GBT009 at Unity Hospital in Rochester, New York. GBT009 gives off a variety of pro-regenerative growth factors and cytokines which help repair damaged tissue and reduce inflammation, ultimately augmenting the body's ability to heal itself.

23 Mar 2010

University Physicians & Surgeons select McKesson for managing medical billing and practice management processes

University Physicians & Surgeons, Inc., the faculty practice of Marshall University’s Joan C. Edwards School of Medicine, has chosen McKesson to manage its medical billing and practice management processes, citing McKesson’s market longevity and reputation for excellence as deciding factors in its choice.

23 Mar 2010

Technique of igniting nanoparticles with low-intensity laser may help destroy cancer cells from within

University of Florida engineering researchers have found they can ignite certain nanoparticles using a low-power laser, a development they say opens the door to a wave of new technologies in health care, computing and automotive design.

19 Mar 2010

USPTO issues Notice of Allowance for Quick-Med Technologies' NIMBUS technology

Quick-Med Technologies, Inc., a leader in developing innovative antimicrobial technologies for the healthcare and consumer markets, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance for intellectual property that significantly adds to the current patent coverage for the Company's NIMBUS technology.

17 Mar 2010

New study finds green tea extract may prevent Alzheimer's disease and dementia

Long known to be beneficial in heart disease, diabetes and some cancers, a new study finds a specific green tea extract may delay or prevent Alzheimer's disease and dementia. A. Holliday & Company's "Teawell 50," is a 50 percent pure extraction of EGCG (epigallocatechin gallate) – a flavonoid which is the most potent of four major catechins in green tea.

15 Mar 2010

Halozyme Therapeutics reports net loss of $12.7M for fourth-quarter of 2009

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the fourth quarter and year ended December 31, 2009.

12 Mar 2010

Independently-conducted studies confirm significant bioavailability of orally delivered insulin

ACCESS PHARMACEUTICALS, INC. announced that it has received reports of significant bioavailability of orally delivered insulin in two independently-conducted animal studies. The studies, which confirm earlier findings, were performed as part of on-going work with commercial collaborators that are evaluating Access' Cobalamin™ Oral Drug Delivery Technology.

12 Mar 2010

High-intensity workout as effective as traditional types of exercise: study

The usual excuse of "lack of time" for not doing enough exercise is blown away by new research published in The Journal of Physiology.

12 Mar 2010

StemCells reports net loss of $5.23M for fourth-quarter fiscal 2009

StemCells, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. The Company's results include the operations of Stem Cell Sciences Plc (SCS) since April 1, 2009.

11 Mar 2010

Discovery Laboratories reports net loss of $6.1M for fourth-quarter 2009

Discovery Laboratories, Inc. today announces financial results for the fourth quarter ended December 31, 2009 and provides a business update.

10 Mar 2010

Organisational justice causes feelings of embitterment and burn-out at work

New findings suggest the role of organisational justice in causing feelings of embitterment and burn-out at work. Professor Tom Sensky (Imperial College, London, UK) analyzes these data in the current issue of Psychotherapy and Psychosomatics.

9 Mar 2010

Fenwal receives FDA marketing clearance for Amicus blood cell separator

Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today that the U.S. Food and Drug Administration has granted Fenwal 510(k) clearance to market its Amicus® blood cell separator for collecting human platelets stored in InterSol® platelet additive solution (PAS 3). Fenwal's InterSol® solution was approved by the FDA in December 2009 under a new drug application. It is the first and only platelet additive solution now available in America.

9 Mar 2010

PADF and OAS seek donations for Chilean relief and children's clinics

Donations are requested for Chilean relief and to help a group of specialized children's clinics that were damaged by the earthquake and aftershocks, the non-profit Pan American Development Foundation (PADF) and the Organization of American States (OAS) announced.

6 Mar 2010

Soluble Systems, SWAI launch TheraSkin to jumpstart healing in chronic and acute wounds

Soluble Systems, LLC and the Skin and Wound Allograft Institute, a wholly owned subsidiary of LifeNet Health, have signed a noteworthy agreement to launch TheraSkin™, a biologically active human skin allograft designed to jumpstart healing in chronic and acute wounds.

6 Mar 2010

Opexa Therapeutics reports net loss of $1,433,922 for year ended December 31, 2009

Opexa Therapeutics, Inc., a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the year ended December 31, 2009 and provided an update on its progress.

5 Mar 2010

eMix announces additional list of medical facilities that are taking part in beta trials

eMix, a new business venture incubated by DR Systems, today announced an additional list of medical facilities that are taking part in beta trials of eMix, the cloud-based technology for sharing imaging studies and reports. Earlier, eMix had announced a partial list of participating facilities.

5 Mar 2010

Burn News and Research

Small gifts to boost the spirits of cancer patients

One-stop resource for advanced wound care medical reimbursement on Smith & Nephew website

JCOM receives approval from KFDA to commercialize MuGard in Korea

MediciNova reports net loss of $5.9 million for 2009 fourth quarter

Garnet BioTherapeutics commences treatment in GBT009 trial for incisional wounds following breast reconstruction surgery

University Physicians & Surgeons select McKesson for managing medical billing and practice management processes

Technique of igniting nanoparticles with low-intensity laser may help destroy cancer cells from within

USPTO issues Notice of Allowance for Quick-Med Technologies' NIMBUS technology

New study finds green tea extract may prevent Alzheimer's disease and dementia

Halozyme Therapeutics reports net loss of $12.7M for fourth-quarter of 2009

Independently-conducted studies confirm significant bioavailability of orally delivered insulin

High-intensity workout as effective as traditional types of exercise: study

StemCells reports net loss of $5.23M for fourth-quarter fiscal 2009

Discovery Laboratories reports net loss of $6.1M for fourth-quarter 2009

Organisational justice causes feelings of embitterment and burn-out at work

Fenwal receives FDA marketing clearance for Amicus blood cell separator

PADF and OAS seek donations for Chilean relief and children's clinics

Soluble Systems, SWAI launch TheraSkin to jumpstart healing in chronic and acute wounds

Opexa Therapeutics reports net loss of $1,433,922 for year ended December 31, 2009

eMix announces additional list of medical facilities that are taking part in beta trials

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News